The calibration of treatment effects from clinical trials to target populations Standard practice teaches that randomized clinical trials should be preferred to observational studies if the aim is to obtain unbiased estimates of efficacy. It is often acknowledged that treatment efficacy might differ in the general population than in the clinical trial, but the source of those differences is often poorly understood or not regarded as important. Substantive differences between RCT and observational study results are typically ascribed to confounding of the latter.
Recent literature [1, 2] suggests that differences between the results seen in an RCT and in an observational study can be larger than expected not because of confounding, but because of differences between their respective patient populations. These efficacy estimates can differ enough to change treatment recommendations. The paper by Weisberg et al. in this issue [3] is a very clear and innovative example of such emerging literature. But there is another important message that one should derive from this work. That is, RCT results are useful only if we can calibrate their results to predict treatment efficacy in the target population of interest. This editorial makes the case for why calibration requires both clinical knowledge from observational studies, and new statistical insights.
Calibration based on pre-treatment exclusion criteria
To do such a calibration we need to first record pre-treatment factors that we know can differ between the RCT and the target patient population. These factors can exist by design, as with exclusion criteria discussed by Weisberg et al. or exist unintentionally, as with factors driving patients to volunteer for the RCT. We can use these factors to predict the effect that would be experienced in the target population. For example, suppose the target population has a 50 : 50 mix of patients with and without a family history that increases the risk of suicide under standard treatment. Suppose further that in order to reduce the number of patients with high risk of suicide in a clinical trial, we restrict enrollment based on family history, producing an RCT with a 20% prevalence of the risk factor. We can then predict the effect of the treatment on the target population by applying the efficacy results we see in the 20% subgroup with family history in the RCT to the 50% with family history in the target population, and by applying the results we see in the 80% without family history in the RCT to the 50% without family history in the target population. This is a direct way to address the problem raised by Weisberg et al. for differences due to exclusion criteria used by physicians, because such criteria are based on factors that are measured.
The need to calibrate post-treatment measurements and mediators
Differences between the RCT participants and the target population can also manifest in variables measured after treatment. An aim of this editorial is to show why calibrating such differences is important, and why this calibration is substantially more challenging and requires new methods.
To calibrate such differences, clinical knowledge needs to be used to determine which RCT components are generalizable to the patient population. When it comes to post-treatment measures, such as adherence, the problem is that standard methods are deficient because they can only generalize components that are not causal effects of treatment. Yet causal effects are of most interest for estimation because they are arguably most generalizable. Methods should thus be developed to predict the outcomes in a target population, by calibrating it to the RCT on certain key causal effects. The meaning of this can be clarified only if we become more specific about certain ß Society for Clinical Trials 2009 SAGE Publications 10.1177/1740774509103868
fundamental concepts, as we do below. Such predictions can be markedly different and more plausible than standard predictions, as also shown below.
To describe what such methods must do, we will use the example of an RCT with noncompliance (or more generally, any mediator of the treatment effects). This RCT compares assignment to old and new treatments, labeled with 'Z' and the outcome Y is survival at 1 year (Figure 1(a) ). However, after assignment to a treatment, some patients do not comply, and actually receive either the old or the new treatment. To be concrete, we will describe the RCT in terms of potential outcomes [4, 5] and let:
As we can see, some of the above characteristics cannot be observed, namely the treatment received and the outcome that would have been measured if patient i had been assigned to a treatment different than the one (namely, Z i ) they were actually assigned. Consequently, the RCT result can be represented based either on the observed data, or on the more fundamental, partly unobserved data. This difference can impact how one does calibration to a new study, so we briefly summarize here these two ways of representation. This equation says that the joint probability of the observed survival and received treatment, given the assigned treatment, is the product of the probability of the received treatment given the assigned treatment and the probability of the survival, given the received treatment and the assigned treatment (which may not be the same).
(b) Principal causal effect distributions to represent the experiment
To describe this, we first classify patients into three strata denoted by S: -S ¼ 'Never-takers': patients who would not take the new treatment in the RCT, no matter the assignment (D i (old) ¼ D i (new) ¼ old) -S ¼ 'Always-takers': patients who would take the new treatment in the RCT, no matter the assign-
: patients whose taking of treatment would agree with their assignment no matter what that would be, (D i (old) ¼ old and
We assume there are no 'defiers', i.e., no patients who would do the opposite no matter the assignment, an assumption called monotonicity [5] .
These groups parallel Weisberg et al.'s four groups, in the sense that the membership of a patient to each such group does not change with actual assignment [6, 7] . Here, however, these groups are critical also because they form strata in which to define true causal effects on survival. For this reason, these strata are known as 'principal strata' [8] . Principal strata allow us to define causal effects that account for compliance. For example, the comparison between:
is the only experimental comparison for which the contrast between assignment to z ¼ old and z ¼ new is precisely the same as the contrast between actually receiving the old versus the new treatment.
The observed data and the principal strata are connected, in the sense that: This equation says that the probability of the observed outcome and received treatment, as a function of assigned treatment, is a function of the distribution of principal strata and of the survival probability within principal strata. Figure 1(a) 
Assuming the exclusion restriction, the distributions of pr(S) and pr(Y(z) | S) (left side of Figure 1(a) ) can be deduced from the observed data (right side of Figure 1(a) ). The figure shows that 60% of the original population were compliers, and that in this subgroup the probability of survival is 15% if assigned to the old treatment versus 25% if assigned the new treatment.
Methods that can allow better calibration of post-treatment variables (mediators)
The preceding framework now allows us to explain why the distinction between representations (1) (standard conditional distribution) and (3) (distributions based on principal strata) implies that there are different ways of generalizing results from the RCT to a study in the target population. In this target study, we assume we have an arm that assigns a large number of people to the new treatment, and an arm that originally assigns a smaller number of people to the standard treatment, to measure compliance in the target population. Here, distinguish the distributions of principal strata and of outcomes given principal strata between the RCT in which we observe all data (Figure1 (a) ) and the target study (Figure 1(b) ), respectively:
Principal strata
Outcome distributions RCT : pr RCT fDðoldÞ;
DðnewÞg pr RCT fYðzÞjDðoldÞ,
DðnewÞg ð4Þ
Target : pr target fDðoldÞ; DðnewÞg
The left sides of (4) and (5) are principal strata, because principal strata as defined in (b) are simply another way to describe a value of both D(old) and D(new).
Because we see all the data in the RCT, and only compliance data but not the outcome data in the target study, all distributions above are estimable empirically except pr target {Y(z) | D(old),D(new)}.
There is often interest to predict the outcomes Y obs i in the target study before waiting to measure them. This could be done based on their predictive distribution, denoted by pr target {Y obs | D obs , Z}. Because the distributions (5) 
where D mis are the missing potential values of D(z).
Readers not interested in the integral can take (6) to simply mean that we could predict the outcome from its correct distribution if we knew the proportions of principal strata, and the distribution of the outcome within principal strata. Without waiting for any outcome Y obs , however, the correct predictive distribution in (6) is not available because pr target {Y(z) | D(old), D(new)} is not available. To address this, the standard approach predicts the outcomes Y obs in the target study using the predictive distribution from the RCT, pr RCT {Y obs | D obs , Z}, effectively replacing in (6) both distributions of (5) with those of (4). This is represented in Figure 1(a) , and the right panel of (b), by the lines connecting the observed data of the two figures. The problem with this approach is that the target study can differ from the RCT in either the distribution of principal strata or the potential outcomes given principal strata, in which case the RCT predictive distribution will be incorrect for the target study. This may help to explain empirical evidence that regressions pr RCT {Y obs | D obs , Z} in one RCT can be quite different in another study with the same type of outcome and assigned and received treatment [9] .
To address this, consider, alternatively, replacing only the outcome component in the right side of (6) with that of the RCT, to obtain the synthetic predictive distribution defined as, pr SYNTHESIS ðY obs jD obs , Z ¼ zÞ 
